Skip to main content

Advertisement

ADVERTISEMENT

News

News
10/29/2024
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the...
10/29/2024
First Report Managed Care
News
10/29/2024
This systematic review explores the impact of cardiovascular and lung comorbidities on pulmonary arterial hypertension patients, revealing the need for tailored management for this high-risk population.
This systematic review explores the impact of cardiovascular and lung comorbidities on pulmonary arterial hypertension patients, revealing the need for tailored management for this high-risk population.
This systematic review explores...
10/29/2024
First Report Managed Care

Advertisement

News
10/28/2024
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the...
10/28/2024
First Report Managed Care
News
10/25/2024
Recent advancements in the treatment of pulmonary arterial hypertension have shifted clinical practices toward combination therapies, particularly highlighting the role of riociguat.
Recent advancements in the treatment of pulmonary arterial hypertension have shifted clinical practices toward combination therapies, particularly highlighting the role of riociguat.
Recent advancements in the...
10/25/2024
First Report Managed Care
News
10/25/2024
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of...
10/25/2024
First Report Managed Care

Advertisement

News
10/25/2024
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study...
10/25/2024
First Report Managed Care
News
10/24/2024
Pfizer receives FDA approval for Abrysvo, the first RSV vaccine for adults under 50 at risk of lower respiratory tract disease, marking a significant milestone in respiratory health.
Pfizer receives FDA approval for Abrysvo, the first RSV vaccine for adults under 50 at risk of lower respiratory tract disease, marking a significant milestone in respiratory health.
Pfizer receives FDA approval for...
10/24/2024
First Report Managed Care
News
10/23/2024
A comprehensive review of multiple sclerosis causes, forms, and treatments.
A comprehensive review of multiple sclerosis causes, forms, and treatments.
A comprehensive review of...
10/23/2024
First Report Managed Care

Advertisement

News
10/23/2024
The molecular characteristics of primary and metastatic tumors in patients with upper tract urothelial carcinoma (UTUC) are mostly stable, suggesting that oncologists may be able to use analyses of primary tumor samples for molecular...
The molecular characteristics of primary and metastatic tumors in patients with upper tract urothelial carcinoma (UTUC) are mostly stable, suggesting that oncologists may be able to use analyses of primary tumor samples for molecular...
The molecular characteristics of...
10/23/2024
First Report Managed Care
News
10/23/2024
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise...
10/23/2024
First Report Managed Care

Advertisement